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SIGNIFICANCE
Acne is one of the commonest dermatological diseases and 
this is a first large-scale case control study aiming to reveal 
psychosocial impact. This analysis was based on a mul-
ticenter study including 213 acne patients over 18 years 
and 213 age-sex matched controls. We found that patients 
with acne are more likely to express anxiety, depression, 
pain and discomfort, and suicidal thoughts than the gene-
ral population. Clinicians must be alert to these symptoms 
and where present consider the possibility of an underlying 
psychiatric component. This awareness may improve re-
cognition of patient concerns and allow clinicians to opti-
mize treatment.
The link between acne and psychiatric morbidities has 
been demonstrated in many studies; however, large 
scale studies aiming to reveal the psychosocial impact 
of acne are rare. The aim of this study was to assess 
the psychological burden of adult acne patients. This 
analysis was based on a multicenter study including 
213 acne patients and 213 controls from 13 European 
countries. The Hospital Anxiety and Depression Scale 
(HADS), Dermatology Life Quality Index, and EuroQol 
5 dimensions 3 levels scores of the patients with acne 
were analyzed. Patients with acne (n = 213) had hig-
her HADS scores for anxiety (mean ± standard deviation 
6.70 ± 3.84) and depression (3.91 ± 3.43) than the con-
trols (p < 0.001 for both). For patients with acne, 40.6% 
reported that they were very concerned about their 
skin disease, 12.3% had suicidal ideation, and, among 
those, 10 (4%) patients implied that acne was the cau-
se of their suicidal thoughts. After adjusting for other 
variables, patients who had suicidal ideation (p = 0.007, 
and adjusted odds ratio  3.32 [95% confidence interval 
(CI): 1.39–7.93]) and stressful life events (p < 0.001, 
and adjusted OR 5.85 [95% CI: 2.65–12.86]) had a 
greater chance of fulfilling the HADS criteria for anx-
iety. This study highlights the need for a psychothera-
peutic approach in order to recognize the concerns of 
acne patients and optimize their treatment.
Key words: acne vulgaris; anxiety; depression; health con-
cerns; quality of life; multicenter study.
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Acne is one of the most common dermatological diseases, with a prevalence of 85% in adolescents, 
although it may also appear or extent in adult ages (1). 
A systematic analysis in the “Global Burden of Disease 
Study 2010” reported that acne is the 8th most frequent 
disease worldwide (2). Acne may affect individuals 
not only physically but also sociopsychologically. In 
previous studies, psychological comorbidities, such as 
depression, social anxiety, and suicidal thoughts, have 
been mostly reported in adolescent populations with acne 
(3, 4). Other psychological effects of acne, including em-
barrassment, impaired self-image, lowered self-esteem, 
self-consciousness, frustration, and anger, have also 
been identified (5). Based on surveys, approximately 
30–50% of patients between 12–20 years of age with 
acne exhibit psychological responses, including anxiety, 
depression, lowered self-esteem, and low self-confidence 
(6). However, there is a lack of knowledge regarding the 
psychosocial burden of acne in adult ages.
It is important to understand the co-existing psycho-
logical issues that affect acne patients’ psychological 
well-being in order to optimize the therapeutic approach 
(7). The aim of this study was to investigate population 
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characteristics, dermatological quality of life, depression, 
anxiety, and suicidal thoughts in adult patients with acne 
and compare them with those of healthy controls across 
13 European countries.
MATERIALS AND METHODS
This study was based on a multicenter, observational, cross-
sectional study in 13 European countries (8). Patients were 
recruited from dermatological outpatient clinics from November 
2011 to February 2013. Patients met the inclusion criteria if they 
were over 18 years of age, understood the local language, and 
did not have psychosis. Data were provided for 213 acne patients 
out of the total 3,635 outpatients in the main study, and 213 age- 
and sex-matched controls were randomly chosen out of 1,359 
healthy subjects. The control group consisted of healthy workers 
without any dermatological disease. All patients participating in 
the study, including controls, were examined by a dermatologist. 
Sociodemographic variables (sex, age, ethnicity, marital status), 
self-reported socioeconomic status (low, middle, high), and educa-
tion (primary education, secondary education, higher education, 
university) were recorded. Additionally, primary and secondary 
dermatological diagnoses, severity of the disease (mild, moderate, 
severe), the presence of another chronic disease, suicidal ideation 
(yes, no), and whether the skin disease was the cause of the suicidal 
ideation (yes, no) were recorded. Emotional stress was assessed 
with the following question: “Have you experienced any stressful 
life events during the last 6 months?”. To the question, “What is 
your level of concern about your skin disease?”, patients could 
answer “high”, “medium”, or “low”. The following questionnaires 
were also given to each participant: The Dermatology Life Quality 
Index (DLQI; (9) consists of 10 questions concerning patients’ 
perceptions of the impact of skin diseases on different aspects of 
their health-related quality of life over the last week. Each question 
is scored from 0 to 30, giving a possible score range from 0 (no 
impact of skin disease on quality of life) to 30 (maximum impact 
on quality of life). Categories are as follows: 0–1, no effect at all 
on the patient’s life; 2–5, small effect on the patient’s life; 6–10, 
moderate effect on the patient’s life; 11–20, very large effect on the 
patient’s life; and 21–30, extremely large effect on patient’s life.
The Hospital Anxiety and Depression Scale (HADS; (10) is a 
well-validated scale to assess depression and anxiety. It includes 7 
items assessing anxiety and 7 for depression, each with 4 possible 
responses. For each dimension of anxiety and depression, a score 
from 0 to 7 is considered a normal case, from 8 to 10 a borderline 
case, and from 11 to 21 a case in need of further examination or 
requiring treatment. 
The EuroQol 5 dimensions 3 levels (EQ-5D-3L; (11) is compo-
sed of two parts: the EQ-5D-3L descriptive system and the EQ 
Visual Analogue Scale (EQ-VAS). This scale provides a simple 
descriptive profile and a single index value for general health 
status. Participants are asked to choose one of 3 possible answers 
for 5 questions on mobility, self-care, usual activities, pain and 
discomfort, and anxiety and depression: level 1 (no problems), 
level 2 (some problems), or level 3 (extreme problems). The EQ-
VAS records participants’ self-rated health on a vertical visual 
analogue scale from 0 to 100 (0 = “worst imaginable health state,” 
100 = “best imaginable health state”).
Descriptive statistics are given as number and percentage for 
categorical variables and as the mean and standard deviation (SD) 
for numeric variables. Comparisons between two independent 
groups were made using the Mann-Whitney U test when they 
were not normally distributed. More than two independent group 
comparisons were made using a one-way analysis of variance 
(ANOVA) when they were normally distributed and using the 
Kruskal-Wallis when they were not. Categorical variables were 
compared using a χ2 test. Spearman’s correlation coefficient test 
was used to analyze the association between numerical variables. 
A logistic linear regression analysis was used to determine the 
responsible factors. The statistical alpha (level of significance) 
level was accepted as p < 0.05.
RESULTS
Of the 3,635 patients with dermatological disease who 
completed the original study (8), 213 (5.9%) were acne 
patients, 132 (62%) were women, and 81 (38%) were 
men, and the mean ± SD age was 24.4 ± 7.1 years. The 
control group consisted of 132 women and 81 men, 
with a mean ± SD age of 24.6 ± 6.3 years. The following 
13 countries were involved in the study: Belgium, 
Germany, Denmark, Spain, France, Hungary, Italy, the 
Netherlands, Norway, Poland, Russia, Turkey, and the 
United Kingdom. Turkey, Italy, and the United Kingdom 
contributed the most acne patients to the sample, with 75 
(35%), 31 (14.5%), and 30 (14 %) patients, respectively. 
Table I. A comparison of the results of the Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS), and 
EuroQol 5 dimensions (EQ-5D) questionnaires among acne patients from different countries
Country n
DLQI
Mean  ± SD
HADS 
Anxiety
Mean  ± SD
HADS 
Depression
Mean  ± SD
EQ-5D 
Mobility
Mean  ± SD
EQ-5D Self-
care
Mean  ± SD
EQ-5D Usual 
activities
Mean  ± SD
EQ-5D Pain 
or discomfort
Mean  ± SD
EQ-5D Anxiety 
or depression
Mean  ± SD
EQ-5D Health 
state
Mean  ± SD
Turkey 75 6.47 ± 4.11 6.36 ± 3.31 3.79 ± 3.24 1.03 ± 0.16 1.01 ± 0.12 1.04 ± 0.20 1.12 ± 0.33 1.80 ± 0.52 79.1 ± 12.7
Italy 31 5.97 ± 5.27 6.87 ± 3.59 4.06 ± 3.53 1.00 ± 0.00 1.03 ± 0.18 1.06 ± 0.25 1.39 ± 0.50 1.39 ± 0.50 82.1 ± 11.1
UK 30 6.87 ± 5.70 7.67 ± 4.79 3.80 ± 3.60 1.03 ± 0.18 1.00 ± 0.00 1.03 ± 0.18 1.10 ± 0.31 1.37 ± 0.49 83.3 ± 13.2
Norway 23 8.74 ± 7.30 6.74 ± 4.89 3.65 ± 3.79 1.13 ± 0.34 1.00 ± 0.00 1.26 ± 0.45 1.39 ± 0.50 1.70 ± 0.82 75.3 ± 20.4
Russia 13 6.00 ± 4.60 6.77 ± 2.89 4.23 ± 2.92 1.15 ± 0.38 1.15 ± 0.38 1.15 ± 0.38 1.38 ± 0.51 1.77 ± 0.44 64.1 ± 22.0
Belgium 11 4.18 ± 5.79 7.73 ± 4.34 4.45 ± 4.48 1.00 ± 0.00 1.00 ± 0.00 1.20 ± 0.42 1.30 ± 0.48 1.70 ± 0.67 71.9 ± 22.2
Spain 9 0.78 ± 1.39 5.33 ± 3.00 2.22 ± 1.99 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 87.2 ± 12.5
Poland 6 3.83 ± 2.93 2.67 ± 1.86 2.33 ± 1.97 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 1.17 ± 0.41 1.33 ± 0.52 92.8 ± 5.1
Germanya 4 5.25 ± 4.50 7.00 ± 2.16 5.75 ± 2.36 1.00 ± 0.00 1.00 ± 0.00 1.25 ± 0.50 1.75 ± 0.50 1.50 ± 0.58 75.0 ± 19.2
Denmarka 3 8.33 ± 8.02 7.00 ± 6.08 7.33 ± 4.73 1.67 ± 1.15 1.00 ± 0.00 1.67 ± 0.58 1.67 ± 0.58 1.67 ± 0.58 76.7 ± 22.6
Hungarya 3 2.00 ± 2.65 7.33 ± 5.69 4.67 ± 4.51 1.00 ± 0.00 1.00 ± 0.00 2.00 ± 1.00 1.67 ± 0.58 1.67 ± 0.58 91.0 ± 1.4
The Netherlandsa 3 8.67 ± 8.02 5.00 ± 4.36 4.33 ± 4.93 1.33 ± 0.58 1.00 ± 0.00 1.67 ± 0.58 1.33 ± 0.58 1.00 ± 0.00 65.7 ± 12.5
Francea 2 5.00 ± 4.24 8.50 ± 2.12 5.50 ± 6.36 1.00 ± 0.00 1.00 ± 0.00 1.00 ± 0.00 2.00 ± 0.00 1.50 ± 0.71 80.0
p 0.001 0.124 0.801 0.108 0.059 0.019 0.003 <0.001 0.005
aNot included in the statistical analysis.
SD: standard deviation.
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All data are summarized in Table I by country. Table II 
shows the patient and control groups’ sociodemographic 
characteristics, acne severity, level of concern about 
their disease, and the presence of suicidal ideation. The 
mean ± SD duration of skin disease was 5.8 ± 5.2 years. 
Forty percent (n = 86) of the patients had had a high level 
of concern about their acne, and 40% (n = 85) had had 
a stressful life event, which was statistically significant 
compared to controls (p = 0.027). Among the 26 (12%) 
patients with suicidal ideation, 10 (5%) implied that acne 
was the cause of their suicidal thoughts. 
The results of the DLQI, HADS, and EQ-5D ques-
tionnaires for patients and in comparison with the 
controls are given in Table III. The mean HADS anx-
iety scores were 6.70 ± 3.84 for patients with acne and 
5.40 ± 3.43 for controls, and the mean HADS depres-
sion scores were 3.91 ± 3.43 for patients with acne and 
2.71 ± 2.71 for controls (p < 0.001 for both comparisons). 
Also, HADS anxiety scores ≥ 11 (clinical case) were 
reached by 32 (15.1%) acne patients (controls n = 20 
[9.4%], p < 0.001), and HADS depression scores ≥ 11 
(clinical case) were reached by 12 (5.7%) acne patients 
(controls n = 5 [2.3%], p = 0.003). In comparing the pa-
tients with controls in terms of effect size, we observed 
that HADS anxiety scores (0.36), HADS depression 
scores (0.39), and EQ-5D subscale scores for anxiety 
or depression (0.56) and health state (–0.55) had me-
dium effect sizes in patients with acne, which could be 
clinically relevant. 
The mean total DLQI score for all acne patients was 
6.2 ± 5.2, meaning that acne had a moderate effect on 
patient’s life. Thirty-two (15%) of acne patients had a 
DLQI score ≥ 11, meaning acne had a very or extremely 
large impact on their quality of life. Table IV shows 
Spearman’s correlation analysis between questionnaires 
and age, severity of disease, duration of disease, and 
level of concern regarding the disease. We observed that 
there was a statistically significant, moderate correlation 
between DLQI scores and disease severity and between 
DLQI scores and levels of patient concern about their 
acne disease (r = 0.251, p < 0.001; r = 0.422, p < 0.001, 
respectively). Moreover, the level of patient concern 
about acne was positively correlated with HADS and 
EQ-5D scores and negatively correlated with EQ-VAS 
scores. Age had only weak correlation with pain and 
discomfort scores on the EQ-5D.
The regression analysis for clinical anxiety and depres-
sion (HADS score ≥ 11) is given in Table V. The data 
showed that the female sex had an increased likelihood 
of having abnormal anxiety (OR 2.451 [95% CI: 1.072–
5.607]). Patients with a stressful life event in the past 6 
months (OR 5.85 [95% CI: 2.659–12.867]) and patients 
with suicidal ideation (OR 3.323 [95% CI: 1.39–7.936]) 
Table II. Characteristics of the study population
Patients 
(n = 213)
Controls 
(n = 213) p
Age, years, mean ± SD (range) 24.4 ± 7.1 (18–66) 24.6 ± 6.3 (18–66) 0.078
Duration of skin disease, years, 
mean ± SD (range)
5.8 ± 5.2 (1–32)
Sex, n (%)
Male 81 (38.0) 81 (38.0) 1.000
Female 132 (62.0) 132 (62.0)
Education, n (%)
Low education level 46 (21.6) 32 (15.2) 0.181
Higher education level 80 (37.6) 79 (37.4)
University 87 (40.8) 100 (47.4)
Ethnicity, n (%)
Home 196 (92.5) 191 (91.8) 0.812
Foreign 16 (7.5) 17 (7.5)
Marital status, n (%)
Single 159 (77.6) 142 (66.7) 0.018
Married 44 (21.5) 67 (31.5)
Divorced 1 (0.5) 4 (1.9)
Widowed 1 (0.5) 0 (0.0)
Socioeconomic status, n (%)
Low 32 (15.1) 54 (25.8) 0.010
Middle 161 (75.9) 145 (69.4)
High 19 (9.0) 10 (4.8)
Stressful life event, n (%)
Yes 85 (40.5) 63 (30.1) 0.027
No 125 (59.5) 146 (69.9)
Suicidal ideation, n (%)
Yes 26 (12.3) 14 (8.0) 0.160
No 185 (87.7) 162 (92.0)
Level of concern about skin disease, n (%)
Low 31 (14.6)
Medium 95 (44.8)
High 86 (40.6)
Disease severity, n (%)
Mild 77 (36.7)
Moderate 97 (46.2)
Severe 36 (17.1)
SD: standard deviation.
Table III. Results of the Dermatology Life Quality Index, Hospital Anxiety and Depression Scale, and EuroQol 5 dimensions questionnaires 
among patients and controls
Patients
n = 213
Mean ± SD (95% CI)
Controls
n = 213
Mean ± SD (95% CI)
Effect size
(95% CI lower/upper limit)
p-value
Patients
vs. controls
Dermatology Life Quality Index 6.19 ± 5.23 (5.49–8.90)
Hospital Anxiety and Depression Scale
Anxiety 6.70 ± 3.84 (6.18–7.22) 5.40 ± 3.43 (4.93–5.86) 0.36 (–016/0.82) < 0.001
Depression 3.91 ± 3.43 (3.45–4.37) 2.71 ± 2.71 (2.35–3.08) 0.39 (–0.07/0.75) < 0.001
EuroQol 5 dimensions
Mobility 1.05 ± 0.24 (1.02–1.09) 1.06 ± 0.24 (1.03–1.09) –0.04 (–0.07/–0.01) 0.544
Self-care 1.02 ± 0.14 (1.00–1.04) 1.01 ± 0.12 (1.00–1.03) 0.08 (0.06/0.09) 0.694
Usual activities 1.11 ± 0.33 (1.07–1.16) 1.10 ± 0.30 (1.06–1.14) 0.03 (–0.01/0.07) 0.726
Pain or discomfort 1.25 ± 0.43 (1.19–1.30) 1.18 ± 0.38 (1.13–1.23) 0.17 (0.12/0.22) 0.092
Anxiety or depression 1.59 ± 0.58 (1.51–1.67) 1.30 ± 0.46 (1.24–1.36) 0.56 (0.48/0.62) < 0.001
Health state (EQ-VAS) 79.0 ± 15.6 (76.9–81.2) 86.7 ± 12.1 (85.1–88.4) –0.55 (–2.69 1.08) < 0.001
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had significantly higher chances of having an abnormal 
anxiety level after adjusting for other variables. 
DISCUSSION
This study outlines a broad assessment of the psychoso-
cial burden of 213 acne patients attending outpatient der-
matology clinics across Europe. We found that the mean 
HADS anxiety and depression scores in acne patients 
were higher than those of controls. Also, almost 15% of 
acne patients had clinically significant anxiety, and 6% 
had depression, which was statistically higher than con-
trols. Lukaviciute et al. (12) reported higher percentages, 
finding that 38.4% of acne patients had anxiety and that 
23.1% patients had depression. Golchai et al. (3) found 
that 68.3% of 82 acne patients had anxiety, but the per-
centage of those with depression and the mean depression 
scores were lower than those of controls. In the current 
study, we only included abnormal/clinical anxiety cases 
(HADS score ≥ 11) to avoid overinterpretation, whereas 
some of these studies included borderline cases (HADS 
score = 8–10), so our anxiety and depression prevalences 
seem lower than what these studies found. In line with 
our study, Kouotou et al. (13) conducted a study with 181 
acne patients and reported that only 7.7% of patients had 
anxiety and 6.6% of patients had depression. In contrast, 
Aktan et al. (14) found no differences in the subscale 
scores for anxiety and depression in acne patients versus 
control subjects. Although anxiety seems to be a more 
common problem than depression in most of studies, 
the prevalence of anxiety and depression appear to be 
highly variable. These discrepancies may be attributed to 
the differences in study populations, which were mostly 
adolescents; differences in the interpretation and cut-offs 
for HADS scores; the use of another screening instrument 
for depression/anxiety; and/or variable sociocultural 
features of different countries. 
Considering the general health of acne patients, the 
mean subscale scores of the EQ-5D for depression/
anxiety demonstrated statistically significant higher 
scores and lower VAS scores versus those of controls. 
To our knowledge, EQ-5D studies in acne are extremely 
scarce (15–17). These studies also found similar results. 
Increased mean scores of anxiety/depression as well as 
lower VAS scores in patients with acne reflect that these 
patients had a significant psychological burden. 
Surprisingly, our results showed that HADS scores 
for anxiety and depression and EQ-5D scores were not 
correlated with disease severity or duration of disease but 
only correlated with the level of concern regarding the 
disease. DLQI scores were only correlated with disease 
severity. In accordance with our findings, Niemeier et al. 
(18) reported that mental problems were not correlated 
with the objective severity of acne. Welp & Gieler (19), 
Table IV. Correlations between disease severity, duration of skin disease, level of concern regarding disease, and scales
Age Disease severity
Duration of skin 
disease
Level of concern over 
skin disease
rho p rho p rho p rho p
Dermatology Life Quality Index –0.077 0.264   0.251 < 0.001 0.041 0.569 0.422 < 0.001
Hospital Anxiety and Depression Scale
Anxiety 0.059 0.393 –0.002 0.971 0.022 0.761 0.266 < 0.001
Depression 0.076 0.275   0.103 0.138 0.038 0.598 0.279 < 0.001
EuroQol 5 dimensions
Mobility 0.050 0.471 –0.041 0.554 0.084 0.238 0.144 0.036
Self-care 0.069 0.324 –0.058 0.403 0.014 0.846 0.157 0.023
Usual activities 0.133 0.053 0.117 0.093 0.054 0.45 0.180 0.009
Pain or discomfort 0.197 0.004 0.083 0.232 0.149 0.036 0.126 0.068
Anxiety or depression 0.004 0.950 0.046 0.506 –0.093 0.191 0.310 < 0.001
Health state –0.131 0.061 –0.134 0.055 –0.029 0.685 –0.214 0.002
Table V. Anxiety (Hospital Anxiety and Depression Scale (HADS) anxiety score ≥ 11) and depression (HADS depression score ≥ 11) in 
acne patients: Relationships with confounders and risk values
Anxiety HADS score ≥ 11 Depression HADS score ≥ 11
p OR (95% CI) p OR (95% CI)
Age 0.574 1.019 (0.954–1.090) 0.445 1.035 (0.947–1.131)
Female sex 0.034 2.451 (1.072–5.607) 0.621 1.387 (0.379–5.074)
Foreign origin 0.303 0.327 (0.039–2.745) 0.763 1.406 (0.153–12.880)
Marital status (reference: single) 1.000 0.924
  Married 0.959 1.023 (0.429–2.439) 0.490 1.641 (0.401–6.712)
  Divorced 0.999 0.000 (0.000) 0.999 0.000 (0.000)
  Widowed 1.000 0.000 (0.000) 1.000 0.000 (0.000)
Socioeconomic status (reference: low) 0.025 0.014
  Middle 0.008 0.331 (0.145–0.754) 0.004 0.143 (0.038–0.537)
  High 0.547 0.681 (0.195–2.382) 0.163 0.197 (0.020–1.933)
Presence of stressful life event < 0.001 5.850 (2.659–12.867) 0.064 3.524 (0.929–13.369)
Presence of suicidal ideation 0.007 3.323 (1.392–7.936) 0.137 2.830 (0.719–11.142)
OR: odds ratio; CI: confidence interval.
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Yazici et al. (20), Uslu et al. (21), and Aktan et al. (14) 
also found no correlation between clinical status and psy-
chometric findings in acne patients. On the one hand, all 
these results point out that psychological change does not 
necessarily correlate with disease severity, as Niemeier 
et al. (22) stated; on the other hand, they may indicate 
that rather than the severity of the disease, individual 
factors, such as personality disorders, temperaments, 
or body image perceptions, could initiate or exacerbate 
mental problems and determine the psychosocial burden 
of acne patients. There are some studies supporting this 
explanation. For example, Sarkar et al. (23) reported 
that personality disorders were present in 29.2% of 65 
patients with acne. The most common personality dis-
orders were obsessive compulsive personality disorder, 
anxious (avoid ant) personality disorder, and borderline 
personality disorder. Also, patients with a personality 
disorder had a higher number of anxiety and depressive 
disorders (23). Ozturk et al. (24) found that the tempera-
ment properties of worry and pessimism and dependence 
and the character properties of social acceptance and in-
tegrated conscience were more prevalent in acne patients 
than in healthy controls, and they recommended focused 
interventions for temperament and character assessments 
in patients with acne vulgaris. Therefore, the presence 
of conflicting results that indicate a correlation between 
acne severity and depression (in particular) and anxiety 
remains to be solved (12, 25). 
Taking into account risk factors for anxiety and de-
pression, being female emerged as a significant factor 
for anxiety, but not depression. Previous studies have 
also shown that female acne patients are more likely to 
have anxiety and depressive disorders (26). In a recent 
review, it was suggested that sex-specific stress, such as 
menstruation, triggers hormonal fluctuations and leads 
to psychiatric disorders in acne patients (27). Another 
point was that there was no statistically significant dif-
ference between acne patients and controls regarding the 
presence of suicidal ideation. However, it is notable that 
the logistic regression analyses revealed that patients 
with suicidal ideation had a 3-times higher chance of 
having anxiety, but not depression. This is interesting 
because depression is usually considered to be a risk 
factor for suicidal thoughts and attempts. In fact, there 
are also controversial results about the link between 
acne, suicidal ideation, and anxiety/depression in the 
current literature. Purvis et al. (28) reported that problem 
acne was associated with an increased probability of 
depressive symptoms, anxiety, and suicide attempts, 
but they found that the number of suicide attempts were 
independent from the presence of depression or anxiety, 
concluding that it was important to ask, especially in 
adolescence, about suicidal ideation directly. Rehn et 
al. (29) investigated the association between depression, 
anxiety, and suicidal ideation in young males with acne 
and did not find any relationship between acne and the 
presence of depressive symptoms and suicidal ideation. 
They denoted that suicidal ideation is irrespective of 
the presence of depressive symptoms. Saitta et al. (30) 
pointed out that awareness of suicide risk in young pa-
tients is particularly important because younger patients 
demonstrate a higher fre quency of poor self-esteem, 
interpersonal con flict with friends, and difficulties at 
school, which are general risk factors for suicide during 
a vulnerable period like adolescence (31, 32). Halvor-
sen et al. (4) suggested that acne is an independent risk 
factor for suicidal ideation in adolescents. We found 
no difference between patients and controls in terms of 
suicide ideation. Undoubtedly, one should consider that 
the vast majority of all these studies were carried out in 
young age groups, whereas the age range in our study 
group was broader. 
Furthermore, patients who reported a stressful event 
in the last six months had a five times greater chance of 
having anxiety. Recently, Bondade et al. (33) studied 100 
acne patients and reported that undesirable life events 
were present in 65 patients and 50 controls, which was 
statistically significant. Although the role of stressful 
life events and stress in precipitation or exacerbation of 
acne is still an unknown, these factors can contribute to 
psychiatric comorbidity in acne as shown in many studies 
and also in ours. So, in order to optimize the patient’s 
wellbeing, treatment should include not only conventio-
nal acne treatments but also a psychosomatic approach 
that includes stress management, relaxation techniques, 
educational programs, and appropriate medication for 
patients with a psychiatric comorbidity. 
The most important strength of this study is that it is 
the first acne study to evaluate the psychosocial aspects 
of acne across Europe in adults, was not restricted to the 
adolescent age group, and was not restricted to a given 
geographic location or culture. On the other hand, the 
fact that the total number of patients with acne was not 
large, given the very high prevalence of the condition, 
was a limitation. A possible selection bias was that the 
recruitment centers were mainly academic centers and 
may not have been representative of clinical practice 
across each country. 
In conclusion, we found that patients with adult acne 
may be more likely to express anxiety and depression 
than the general population, although the association 
between adult acne and depression was less substantial. 
Being female, having undergone stressful life events, and 
thinking suicidal thoughts were associated with anxiety 
symptoms. In addition, general health appears to be 
impaired in patients with acne. Clinicians must be alert 
to these symptoms and, when they are present, consider 
the possibility of an underlying psychiatric component. 
This awareness may improve the recognition of patient 
concerns and allow clinicians to optimize treat ment and 
prevent or reduce patients’ non-compliance with the 
treatment plan. 
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